Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2020
Academia developing medicines for rare diseases to receive free EMA scientific advice
23 June 2020 - To further encourage the development of treatments for rare diseases, EMA will waive all fees for ...
Posted by Michael Wonder on 01 Apr 2020
Regulatory information - 1.6% increase in fees from 1 April 2020
1 April 2020 - General, non-pharmacovigilance fees payable to EMA by applicants and marketing-authorisation holders are increasing by 1.6% on ...
Posted by Michael Wonder on 14 Mar 2020
COVID-19: developers of medicines or vaccines to benefit from free scientific advice
13 March 2020 - EMA provides full fee waivers for scientific advice applications from developers of potential therapeutics (to treat ...
Posted by Michael Wonder on 01 Apr 2019
Regulatory information – 1.7% increase of fees from 1 April 2019
1 April 2019 - General, non-pharmacovigilance fees payable to EMA by applicants and marketing-authorisation holders are increasing by 1.7% on ...
Posted by Michael Wonder on 04 Mar 2019
Regulatory information – adjusted fees for applications to EMA from 1 April 2019
1 March 2019 - The EMA reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for ...
Posted by Michael Wonder on 28 Mar 2018
EMA to raise MAH and applicant fees by 1.7% in April
28 March 2018 - As part of the EMA's alignment with the inflation rate, the agency announced on Tuesday that ...